Global Injectable Blood Thinners Market Growth 2025-2031

Publication ID:

LPI02257276

Publication Date:

March 3, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Injectable Blood Thinners market size is predicted to grow from US$ 172 million in 2025 to US$ 207 million in 2031; it is expected to grow at a CAGR of 3.2% from 2025 to 2031.
Blood thinners are medications taken orally or intravenously (through a vein) to prevent a blood clot. Blood clots can stop the flow of blood to the heart, lungs, or brain. They can cause a heart attack or stroke. Some anticoagulant medicines are given as a shot (injection). Anticoagulants are also called blood thinners. Examples of these medicines include low-molecular-weight heparin and fondaparinux.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
The 鈥淚njectable Blood Thinners Industry Forecast鈥� looks at past sales and reviews total world Injectable Blood Thinners sales in 2024, providing a comprehensive analysis by region and market sector of projected Injectable Blood Thinners sales for 2025 through 2031. With Injectable Blood Thinners sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable Blood Thinners industry.
This Insight Report provides a comprehensive analysis of the global Injectable Blood Thinners landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable Blood Thinners portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Injectable Blood Thinners market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable Blood Thinners and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable Blood Thinners.
This report presents a comprehensive overview, market shares, and growth opportunities of Injectable Blood Thinners market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
LMWH
Unfractionated Heparin
Fibrinolytics
Other
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Genentech (Roche)
Boehringer Ingelheim
Aspen
Pfizer
Hepalink
King-friend
CSBIO
Amphastar Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Injectable Blood Thinners market?
What factors are driving Injectable Blood Thinners market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Injectable Blood Thinners market opportunities vary by end market size?
How does Injectable Blood Thinners break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Injectable Blood Thinners Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Injectable Blood Thinners by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Injectable Blood Thinners by Country/Region, 2020, 2024 & 2031
2.2 Injectable Blood Thinners Segment by Type
2.2.1 LMWH
2.2.2 Unfractionated Heparin
2.2.3 Fibrinolytics
2.2.4 Other
2.3 Injectable Blood Thinners Sales by Type
2.3.1 Global Injectable Blood Thinners Sales Market Share by Type (2020-2025)
2.3.2 Global Injectable Blood Thinners Revenue and Market Share by Type (2020-2025)
2.3.3 Global Injectable Blood Thinners Sale Price by Type (2020-2025)
2.4 Injectable Blood Thinners Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Injectable Blood Thinners Sales by Application
2.5.1 Global Injectable Blood Thinners Sale Market Share by Application (2020-2025)
2.5.2 Global Injectable Blood Thinners Revenue and Market Share by Application (2020-2025)
2.5.3 Global Injectable Blood Thinners Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Injectable Blood Thinners Breakdown Data by Company
3.1.1 Global Injectable Blood Thinners Annual Sales by Company (2020-2025)
3.1.2 Global Injectable Blood Thinners Sales Market Share by Company (2020-2025)
3.2 Global Injectable Blood Thinners Annual Revenue by Company (2020-2025)
3.2.1 Global Injectable Blood Thinners Revenue by Company (2020-2025)
3.2.2 Global Injectable Blood Thinners Revenue Market Share by Company (2020-2025)
3.3 Global Injectable Blood Thinners Sale Price by Company
3.4 Key Manufacturers Injectable Blood Thinners Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Injectable Blood Thinners Product Location Distribution
3.4.2 Players Injectable Blood Thinners Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Injectable Blood Thinners by Geographic Region
4.1 World Historic Injectable Blood Thinners Market Size by Geographic Region (2020-2025)
4.1.1 Global Injectable Blood Thinners Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Injectable Blood Thinners Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Injectable Blood Thinners Market Size by Country/Region (2020-2025)
4.2.1 Global Injectable Blood Thinners Annual Sales by Country/Region (2020-2025)
4.2.2 Global Injectable Blood Thinners Annual Revenue by Country/Region (2020-2025)
4.3 Americas Injectable Blood Thinners Sales Growth
4.4 APAC Injectable Blood Thinners Sales Growth
4.5 Europe Injectable Blood Thinners Sales Growth
4.6 Middle East & Africa Injectable Blood Thinners Sales Growth
5 Americas
5.1 Americas Injectable Blood Thinners Sales by Country
5.1.1 Americas Injectable Blood Thinners Sales by Country (2020-2025)
5.1.2 Americas Injectable Blood Thinners Revenue by Country (2020-2025)
5.2 Americas Injectable Blood Thinners Sales by Type (2020-2025)
5.3 Americas Injectable Blood Thinners Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Injectable Blood Thinners Sales by Region
6.1.1 APAC Injectable Blood Thinners Sales by Region (2020-2025)
6.1.2 APAC Injectable Blood Thinners Revenue by Region (2020-2025)
6.2 APAC Injectable Blood Thinners Sales by Type (2020-2025)
6.3 APAC Injectable Blood Thinners Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Injectable Blood Thinners by Country
7.1.1 Europe Injectable Blood Thinners Sales by Country (2020-2025)
7.1.2 Europe Injectable Blood Thinners Revenue by Country (2020-2025)
7.2 Europe Injectable Blood Thinners Sales by Type (2020-2025)
7.3 Europe Injectable Blood Thinners Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Injectable Blood Thinners by Country
8.1.1 Middle East & Africa Injectable Blood Thinners Sales by Country (2020-2025)
8.1.2 Middle East & Africa Injectable Blood Thinners Revenue by Country (2020-2025)
8.2 Middle East & Africa Injectable Blood Thinners Sales by Type (2020-2025)
8.3 Middle East & Africa Injectable Blood Thinners Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Injectable Blood Thinners
10.3 Manufacturing Process Analysis of Injectable Blood Thinners
10.4 Industry Chain Structure of Injectable Blood Thinners
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Injectable Blood Thinners Distributors
11.3 Injectable Blood Thinners Customer
12 World Forecast Review for Injectable Blood Thinners by Geographic Region
12.1 Global Injectable Blood Thinners Market Size Forecast by Region
12.1.1 Global Injectable Blood Thinners Forecast by Region (2026-2031)
12.1.2 Global Injectable Blood Thinners Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Injectable Blood Thinners Forecast by Type (2026-2031)
12.7 Global Injectable Blood Thinners Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Injectable Blood Thinners Product Portfolios and Specifications
13.1.3 Sanofi Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Genentech (Roche)
13.2.1 Genentech (Roche) Company Information
13.2.2 Genentech (Roche) Injectable Blood Thinners Product Portfolios and Specifications
13.2.3 Genentech (Roche) Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Genentech (Roche) Main Business Overview
13.2.5 Genentech (Roche) Latest Developments
13.3 Boehringer Ingelheim
13.3.1 Boehringer Ingelheim Company Information
13.3.2 Boehringer Ingelheim Injectable Blood Thinners Product Portfolios and Specifications
13.3.3 Boehringer Ingelheim Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Boehringer Ingelheim Main Business Overview
13.3.5 Boehringer Ingelheim Latest Developments
13.4 Aspen
13.4.1 Aspen Company Information
13.4.2 Aspen Injectable Blood Thinners Product Portfolios and Specifications
13.4.3 Aspen Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Aspen Main Business Overview
13.4.5 Aspen Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Injectable Blood Thinners Product Portfolios and Specifications
13.5.3 Pfizer Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Hepalink
13.6.1 Hepalink Company Information
13.6.2 Hepalink Injectable Blood Thinners Product Portfolios and Specifications
13.6.3 Hepalink Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Hepalink Main Business Overview
13.6.5 Hepalink Latest Developments
13.7 King-friend
13.7.1 King-friend Company Information
13.7.2 King-friend Injectable Blood Thinners Product Portfolios and Specifications
13.7.3 King-friend Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 King-friend Main Business Overview
13.7.5 King-friend Latest Developments
13.8 CSBIO
13.8.1 CSBIO Company Information
13.8.2 CSBIO Injectable Blood Thinners Product Portfolios and Specifications
13.8.3 CSBIO Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 CSBIO Main Business Overview
13.8.5 CSBIO Latest Developments
13.9 Amphastar Pharmaceuticals
13.9.1 Amphastar Pharmaceuticals Company Information
13.9.2 Amphastar Pharmaceuticals Injectable Blood Thinners Product Portfolios and Specifications
13.9.3 Amphastar Pharmaceuticals Injectable Blood Thinners Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Amphastar Pharmaceuticals Main Business Overview
13.9.5 Amphastar Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂